Hematologic Cancers : From Molecular Pathobiology to Targeted Therapeutics, H...

Check the listing for details.

USD 187.02
Condition: see listing
LocationJessup, Maryland US
ShippingUSD 0 · Flat
Seller greatbookprices1
96.4% positive · 316514 feedback
ListingFixedPriceItem · Active
Start time2024-06-25T15:16:00.000Z
End time2024-11-25T16:16:00.000Z
Time leftP12DT20H36M24S
View on eBay Read review
Hematologic Cancers : From Molecular Pathobiology to Targeted Therapeutics, H... Specs
Return shipping will be paid byBuyer
All returns acceptedReturns Accepted
Item must be returned within14 Days
Refund will be given asMoney Back
Book TitleHematologic Cancers : From Molecular Pathobiology to Targeted The
Number of PagesVI, 426 Pages
Publication NameHematologic Cancers: from Molecular Pathobiology to Targeted Therapeutics : From Molecular Pathobiology to Targeted Therapeutics
LanguageEnglish
PublisherSpringer Netherlands
Publication Year2012
SubjectHematology, Oncology, Research
Item Weight29.6 Oz
TypeTextbook
Item Length9.3 in
Subject AreaMedical
AuthorEduardo Sotomayor
SeriesCancer Growth and Progression Ser.
Item Width6.1 in
FormatHardcover
Listing details

Hematologic Cancers : From Molecular Pathobiology to Targeted Therapeutics, Hardcover by Tao, Jianguo (EDT); Sotomayor, Eduardo (EDT), ISBN 9400750277, ISBN-13 9789400750272,

Brand New, Free shipping in the US In the last decade, there has been a remarkable explosion of knowledge in hematologic cancer from basic molecular biology and pathology to clinical therapy. This has led to many new advance and insights in the understanding of pathobiology of malignant hematology. New knowledge of disease molecular pathology, cytogenetic, epigenetic and genomic alterations have provided new strategies to attack and eradicate tumor cells at molecular level and significantly impacted our current therapeutics for hematological malignancies. The recent and ongoing rapid expansion of knowledge in this area has become extensive, dynamic and diffuse over the literature and research publications. This has led to the need to capture and compile the new and current information about hematologic cancer with special emphasis on translation from molecular pathobiology to targeted therapeutics. In this book experts from around the world share their thoughts and knowledge about the pathobiology of hematologic cancer, as well as their view on current treatment approaches and future development in these malignant hematologic diseases. This book is well suited for hematology residents, fellows and hematology-oncology physicians, hematopathologist as well as basic research scientist in the area of hematologic malignancies.